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INTRODUCTION
Patients with inflammatory bowel disease (IBD) may 
develop different extra-intestinal manifestations [1]. 
Among these, Spondyloarthritis (SpA) is the most fre-
quently reported, with an incidence rate of 17-39% [2, 
3]. Early diagnosis of SpA is crucial to perform a tight 
disease control with an impact on its natural history, 
particularly for preventing permanent disabilities [4]. 
However, diagnosis of SpA may be delayed in a sub-
stantial number of IBD patients for different reasons. 
Indeed, the disease may be asymptomatic in the early 
phase, the immunosuppressive/sulfasalazine treatment 
may mask non-specific rheumatic symptoms, or the 
gastroenterologist (and the patient) may underestimate 
inflammatory back pain. On the other hand, an IBD 
may develop in patients with SpA, although the inci-
dence is near 1 case per year of follow-up [5]. Simi-
larly, early diagnosis may be difficult, particularly when 
are present only vague intestinal symptoms that the 
rheumatologist (and the patient) may overlook or an 
immunosuppressive treatment is already performed. It 
is counterintuitive that an early diagnosis could reduce 
the intestinal disease progression, potentially prevent-
ing complications or surgical interventions. 
In the current clinical practice, diagnosis and man-
agement of patients with coexisting IBD and SpA – de-
fined as Enteropathic Spondyloarthritis (ESpA) – are 
usually carried on by a single specialist, which is the 
gastroenterologist or rheumatologist, according to the 
initial disease diagnosed. In such a scenario, a holistic 
patient management is prevented given that one of dis-
ease is beyond the direct field of specialist expertise. To 
overcome such a limitation, we pioneered an integrat-
ed “GastroReumatology” ambulatory in our Hospital, 
on behalf of Italian Society of Gastro-Rheumatology 
(SIGR). 
METHODS
In such dedicated ambulatory, a gastroenterologist 
and a rheumatologist with a long-lasting expertise in 
IBD and SpA, respectively, simultaneously visit those 
patients referred for a suspected ESpA. In detail, pa-
tients were selected based on the presence of some 
clinical indicators – defined “red flags” (Figure 1) – sug-
gestive of SpA and/or IBD, in agreement with Italian 
Expert Panel on the management of coexisting SpA and 
IBD [6]. In detail, a dedicated help-line was created 
where two experienced IBD nurses (AG and FDM), 
specifically trained for both IBD and rheumatic red 
flags, performed a brief interview of patients referred by 
Address for correspondence: Roberto Lorenzetti, Medicina Interna, Gastroenterologia e Reumatologia, Ospedale Nuovo Regina Margherita, Via 
Emilio Morosini 30, 00153 Rome, Italy. E-mail: robertolorenzetti58@gmail.com.
Abstract
Patients with inflammatory bowel disease (IBD) may develop rheumatic diseases, par-
ticularly enterophatic spondyloarthritis (ESpA). Similarly, an IBD may develop in patients 
with SpA. Management of these patients in a dedicated ambulatory could be advanta-
geous. We pioneered an integrated “GastroReumatology” ambulatory where a gastroen-
terologist and a rheumatologist with a long-lasting expertise in IBD and spondyloarthritis, 
respectively, simultaneously visit those patients referred for a suspected ESpA. A total of 
101 different patients with suspected or known IBD and/or a rheumatic disease were vis-
ited. A new diagnosis of ESpA was eventually achieved in 13 (12.9%) patients, and further 
12 patients with an already known ESpA were referred for an appropriate management. 
No cases of IBD in those patients with an established rheumatic disease were observed. 
Early diagnosis of ESpA is possible in a “GastroReumatology” ambulatory.
InnovatIve approach for enteropathIc spondyloarthrItIs early dIagnosIs
B
r
ie
f
 n
o
t
e
s
247
their General Practitioners, and selected those with at 
least 1 suggestive symptom deserving an integrated vis-
it. The nurses fixed the visit even for those patients with 
a doubtful red flag in order to avoid diagnosis missing.
RESULTS
From January 2015 to December 2018, 132 visit ses-
sions were performed, and a total of 101 different new 
patients were evaluated in this integrated ambulatory. 
Patients performing a control visit were excluded from 
this computation. According to standard diagnostic cri-
teria for IBD and rheumatic diseases, 5 patients’ groups 
were identified, as summarized in Table 1. As shown, 
a new diagnosis of ESpA was overall performed in 13 
(12.9%) cases, including 4 patients presenting “red 
flags” for both IBD and SpA (Group 1) and other 9 
patients with known IBD with only vague rheumatic 
symptoms who were eventually diagnosed with a SpA 
by the rheumatologist (Group 2). In addition, further 
12 patients with an already known ESpA where referred 
by other physicians to be followed in our integrated 
“GastroReumatology” ambulatory (Group 3). In 15 pa-
tients with known SpA (Group 4), no cases of IBD were 
found. Moreover, in 26 patients without known IBD or 
SpA, but with musculoskeletal and intestinal symptoms 
(Group 5), no diagnosis of ESpA was performed. A 
joined therapeutic approach was started, and the ap-
propriate follow-up was scheduled for all these patients. 
Of note, in our series, ESpA diagnosis was promptly 
performed in 1 patient of Group 1 who complained of 
chronic abdominal pain and peripheral joints pain for 
which she underwent a number of previous gastroenter-
ology and rheumatology separate visits in other Hospi-
tals during the last 3 years without achieving a definite 
diagnosis. 
DISCUSSION
Diagnosis and management of patients with ESpA 
is generally performed by a single specialist, that is a 
gastroenterologist or rheumatologist, according to the 
initial disease diagnosed. However, by following such 
an approach, the final diagnosis of coexisting IBD and 
SpA is difficult and, not rarely, postponed. Indeed, a 
recent Italian study found that ESpA diagnosis in IBD 
patients was delayed by a mean of 5.2 year [7]. It is 
expected that an early diagnosis of ESpA could be im-
plemented when a patient is referred to a dedicated 
ambulatory, instead of being separately – and some-
times repeatedly – referred to different specialists. The 
probability of response to anti-TNF-α treatment is re-
duced when this rheumatic disease is not diagnosed in 
an early phase, with an increased risk of permanent in-
ability [8]. In our series, a new diagnosis of ESpA was 
performed in 9 (21%) out of 44 IBD patients, as well 
as in all 4 patients presenting with “red flag” for both 
IBD and rheumatic disease. In another Italian, large 
series of IBD patients, the ESpA was diagnosed in 9% 
of cases [7]. Therefore, presence of the so-called “red 
flags” for a rheumatic disease in IBD patients seems 
to be helpful in identifying ESpA. On the contrary, no 
cases of IBD were eventually diagnosed in those with 
a known rheumatic disease complaining of abdominal 
symptoms, most likely due to the small sample size. 
Indeed, in a recent systematic review and meta-anal-
ysis, the prevalence of clinically apparent IBD among 
Table 1
Results of “GastroReumatology” ambulatory activity
Group Setting IBD SpA
1 With “red flags”’ for IBD and SpA
(N = 4)
2 Crohn’s disease
2 Ulcerative Colitis
2 Peripheral spondyloarthritis 
2 Axial spondyloarthritis
2 With IBD evaluated for SpA
(N = 44)
18 Crohn’s disease
26 Ulcerative Colitis
5 Peripheral spondyloarthritis 
1 Enthesitis; 3 Axial spondyloarthritis
3 With known ESpA
(N = 12)
8 Crohn’s disease
4 Ulcerative Colitis
1 Psoriatic spondyloarthritis; 7 Peripheral spondyloarthritis
2 Axial spondyloarthritis; 2 Ankilosing spondyloarthritis
4 With SpA evaluated for IBD
(N =15)
15 no IBD 5 Psoriatic spondyloarthritis; 5 Peripheral spondyloarthritis
4 Axial spondyloarthritis; 1 Enthesitis.
5 Without known IBD or SpA with 
musculoskeletal and intestinal symptoms 
(N = 26)
26 no IBD 14 Fibromyalgia; 12 Orthopedic disorders
Figure 1
Clinical indicators (red flags) suggestive of Spondyloarthritis 
(SpA) or Inflammatory bowel disease (IBD).
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individuals with SpA has been estimated to be approxi-
mately 7% [9]. Based on this estimation, only 1 case 
was expected in our sample size. However, no patient 
in the group 4 presented with elevated faecal calpro-
tectin values or showed endoscopic pictures suggestive 
of IBD. The presence of intestinal symptoms in these 
patients could depend, at least in part, on the use of 
non-steroidal anti-inflammatory drugs (NSAIDs) due 
to SpA symptoms. 
There were some patients with at least one red flag in 
whom nor IBD nor rheumatic disease were diagnosed. 
This would suggest that the presence of these signs are 
sensible, but not specific. Indeed, some symptoms (per-
sistent fever, anaemia, weight loss, chronic diarrhoea) 
included in the “red flags” for IBD are shared with 
other clinical conditions. Moreover, in order to exclude 
a missed diagnosis, even those patients with doubtful 
“red flags” were scheduled for the integrated visit. 
The peculiarity of our Ambulatory consists not merely 
in offering a combined gastroenterological and rheuma-
tologic visit, but that these clinical evaluations were per-
formed by specialists particularly dedicated to IBD and 
SpA, respectively. Our preliminary data would suggest 
that diffusion of such an integrated “GastroRheumatol-
ogy” ambulatory could be implemented, particularly in 
those hospitals where IBD patients are followed. In-
deed, the contemporary presence of a dedicated rheu-
matologist could be advantageous for an early ESpA 
diagnosis, with a prompt and shared management of 
these patients. Moreover, the combined management 
of patients with already known ESpA (Group 3) has re-
sulted very useful in choosing the proper drug treatment 
expected to be effective for both conditions, in agree-
ment with guidelines from Italian Expert Panel [6]. In 
detail, therapy was accordingly changed in 33% of pa-
tients in the Group 3. In the Group 2, the combined 
management allowed a prompt diagnosis of peripheral 
and/or axial articular involvement using the clinical and 
instrumental gold standards for diagnosis. 
In conclusion, our data would suggest that in a dedi-
cated “GastroRheumatology” ambulatory an early diag-
nosis of ESpA is possible, so that a better prevention of 
disease-related disabilities is expected. Last, but not the 
least, a more appropriate utilization of resources and a 
better perceived quality of care by these patients are 
also expected.
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